期刊文献+

靶向抗癌药(As_2O_3)白蛋白纳米球的研究 被引量:8

A Study on the Preparation and Antitumor Efficacy of Human Serum Albumin(HAS) Nanoparticles Containing Arsenous Oxide Bearing Monoclonal Antibody
下载PDF
导出
摘要 目的:研究白蛋白纳米球的制备工艺,并检测偶联单克隆抗体白蛋白纳米球对靶细胞的特异性杀伤作用。方法:采用高温固化法制备白蛋白纳米球,通过正交设计筛选最佳工艺。制备免疫白蛋白纳米球,观察白蛋白纳米球对急性早幼粒细胞白血病M3亚型白血病细胞的特异性杀伤作用。结果:在最佳工艺条件下制备白蛋白纳米球,平均直径为250nm左右,形态圆整。免疫纳米球(0.3μmol/mL剂量组作用48h)对靶细胞(急性早幼粒细胞白血病M3亚型白血病淋巴细胞)杀伤率为(34.12±4.76)%,对正常对照(正常人外周血淋巴细胞)杀伤率仅为(5.37±2.21)%。结论:免疫纳米球对靶细胞具有特异性杀伤作用,而对非靶细胞的杀伤作用较小。 Objective : to study the preparation technology of HAS - nanoparticles, and investigate the peculiar toxicity of HAS - nanoparticles on targeting cells. Methods : we studied the best preparing formula of HAS - nanoparticles by the orthogonal design test. Subsequently HAS - nanoparticles containing arsenous oxide prepared by emulsion - heat stabilization technique were conjugated monoclonal antibodies. Finally the antitumor efficacy of HAS - nanoparticles beating Monoclonal antibody was investigated in M3 acute promyelocytic leukaemia lymphocytes. Results : We got the best formula ,which show the entrapping rate and loading of arsenous oxide was higher and the average particle size was about 250nm. In the study we observed that the death rate of targeting cells after action for 48h hours was 34.12 percent when the dose of drug is 0.3μmol/mL, whereas that of control - group cells was only 5.37 percent. Conclusion : In conclusion, drug targeting can be achieved by incorporating monoclonal antibody on the surface of HAS - nanoparticles.
出处 《中华中医药学刊》 CAS 2007年第8期1633-1635,共3页 Chinese Archives of Traditional Chinese Medicine
基金 江西省科技厅重大专项课题(20041A0300203)
关键词 AS2O3 白蛋白纳米球 靶向抗癌药 arsenous oxide HAS - nanoparticles monoclonal antibody targeting antitumor drugs
  • 引文网络
  • 相关文献

参考文献9

  • 1刘霁辉.亚砷酸注射液不良反应及对策[J].中国医院药学杂志,2005,25(7):687-688. 被引量:9
  • 2张裕能,罗小玲.新银盐法测定食用油中微量砷的方法研究[J].中国公共卫生,2002,18(3):355-355. 被引量:3
  • 3[3]平其能,毕殿洲,邹立家,等.药剂学[M].4版.北京:人民卫生出版社,2002:446
  • 4[4]Santhi K,Dhanaraj SA,Joseph V,et al.A study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5-fluorouracil[J].Drug Dev Ind Pharm,2002,28(9):1171
  • 5[5]Bouchemal K,Briancon S,Perrier E,et al.Nano-emulsion formulation using spontaneous emulsification:solvent,oil and surfactant optimization[J].Int J Pharm,2004,280(1/2):241
  • 6[6]C.Weber,J Kreuter,Langer K.Desolvation process and surface characteristics of HSA-nanoparticles[J].Int J Pharm,2000,196(2):197
  • 7[7]Merodio M,Amedo A,Renedo MJ,et al.Ganciclovir-loaded albumin nanoparticles:characterization and in vitro release properties[J].Eur J Pharm Sci,2001,12(3):251
  • 8[8]Wang YM,Sato H,Adachi I,et al.Optimization of formulation design of chitosan microspheres containing cisplatin[J].J phmarsci,1996,85 (11):1204
  • 9布卡,盛洁,谢蜀生,魏树礼.抗人膀胱癌免疫毫微球的制备及活性检测[J].中华微生物学和免疫学杂志,1996,16(1):54-57. 被引量:21

二级参考文献18

  • 1廖元遂.新银盐法测定化妆品中微量砷的研究[J].中国卫生检验杂志,1995,5(4):201-204. 被引量:7
  • 2刘焕珍.新银盐光度法测定空气中砷化物[J].职业医学,1996,23(3):41-42. 被引量:1
  • 3盛洁,中国医药工业杂志,1995年,30卷,9期,706页
  • 4俞莉章,中华泌尿外科杂志,1991年,12卷,12期,243页
  • 5马爱红,中华泌尿外科杂志,1990年,11卷,195页
  • 6俞莉章,中华泌尿外科杂志,1989年,10卷,131页
  • 7Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide [J].N Engl J Med, 1998,339:1341.
  • 8Huang SY, Chang CS, Tang JL, et al. Acute and chronic arsenic poisoningass-ociated with treatment of acute promyelocytic leukemia[J]. Br J Haematol, 1998,103:1092.
  • 9Shen Y, Shen ZX,Yan H,et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage [J]. Leukemia, 2001,15:735.
  • 10孙慧平,李秀松,于汀,任梅玉,沈志祥.三氧化二砷治疗复发APL外周血象和骨髓象动态变化及意义[J].上海医学,1999,22(2):95-98. 被引量:6

共引文献30

同被引文献137

引证文献8

二级引证文献18

;
使用帮助 返回顶部